

POLITICS

STAT+

FDA official pushes for a dedicated emerging pathogens team to prepare for the next pandemic

By [Simar Bajaj](#) July 21, 2023

[Reprints](#)



Peter Marks, director of the FDA's Center for Biologics Evaluation and Research
GREG NASH/POOL VIA AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added [an amendment](#) creating that team to a key pandemic preparedness bill that must be reauthorized by the [end of September](#). It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and [other medical countermeasures](#). Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

As a [vocal advocate for faster gene therapy approvals](#), Marks has also been pushing for an [Operation Warp Speed for Rare Diseases](#), where a dedicated team would similarly help ensure faster therapeutic development. “We will be launching a pilot — it’ll be a small pilot because it’s very resource intensive — for rare diseases with high unmet medical needs this fall,” Marks said.

NEWSLETTERS

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

SIGN UP

[Privacy Policy](#)

For the emerging pathogens program in particular, the Senate amendment might not survive reconciliation with the House version of the bill, which cleared through the Energy and Commerce Committee on Wednesday.

Marks acknowledged another challenge Thursday. Both programs require the FDA to bolster its recruitment efforts in the face of long-standing staffing challenges.

“The pay at FDA still isn’t industry standard — for private industry,” Marks said, such that agency talent is [regularly poached](#).

Related: [Bernie Sanders adds three drug shortage policies to pandemic preparedness bill](#)

Still, with the FDA working on the frontier of cutting-edge science and novel technologies, “you actually wake up in the morning and really want to go to work,” Marks argued. “That is probably worth something in addition to your salary.”

Artificial intelligence might also help with some of these challenges, he suggested. “As opposed to people in Hollywood who really hate AI, for us, AI could potentially be a real game changer.” Marks says that the FDA has already been using AI for monitoring drug safety and analyzing complex data like whole genome sequencing.

Marks wasn’t sure if Operation Warp Speed for Rare Diseases would ultimately make a difference or if the Emerging Pathogens Preparedness Program would get enacted by Congress. But he was optimistic. “Hopefully this will be something that we will be able to make use of,” Marks says, “but we’ll see where it goes.”

About the Author

[Reprints](#)



Simar Bajaj

News Intern

Simar Bajaj is news intern at STAT supported by the Harvard Institute of Politics and Global Health Institute.

simar.bajaj@statnews.com

Tags

- CORONAVIRUS
- FDA
- POLICY
- STAT+
- VACCINES

Exciting news! STAT has moved its comment section to our subscriber-only app, [STAT+ Connect](#). [Subscribe to STAT+](#) today to join the conversation or join us on [Twitter](#), [Facebook](#), [LinkedIn](#), and [Threads](#). Let's stay connected!

To submit a correction request, please visit our [Contact Us page](#).

STAT+

Catch up on the latest must-read coverage and analysis

READ NOW

STAT+

J&J cuts the price of its lifesaving TB pill by more than half for many low- and middle-income countries

Workforce, capacity constraints slow ramp-up of new Alzheimer's drug Leqembi

KRAS, the ideal cancer drug target that became 'undruggable,' takes on a new glow

EVENTS

2023 STAT Future Summit
Sep. 05, 2023

Putting AI to the Test
Sep. 20, 2023

How to Increase Diversity in Clinical Trials: Strategies and Tools
Sep. 26, 2023

[See More Events >](#)

STAT REPORTS

Deep-dive reports into the breakthroughs that are revolutionizing health care.

Patients speak out: Learning from patient stories to transform health care

2023 Update: Ranking Biotech's Top Venture Capital Firms

Decoding Medicare: 10 Key Decisions and How They're Made


[See More Reports >](#)

Recommended Stories



BIOTECH RACHEL COHRS AND MATTHEW HERPER

Here are the 10 drugs that will be up first for Medicare price negotiation



INSURANCE BOB HERMAN

Feds fine Medicare Advantage plans for overcharging their members



BIOTECH ALLISON DEANGELIS

Former Pear Therapeutics executives start new VC firm, with biotech veteran Bob Langer as adviser



BIOTECH MATTHEW HERPER AND DAMIAN GARDE

Winners and losers from Medicare's list of drugs subject to price negotiation



MATT'S TAKE MATTHEW HERPER

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

STAT

Reporting from the frontiers of health and medicine

TRENDING:

- STAT+
- HEALTH
- BIOTECH
- FIRST OPINION
- HEALTH TECH
- PHARMA

COMPANY

- [About](#)
- [Our Team](#)
- [Contact Us](#)
- [Careers](#)
- [Diversity & Inclusion](#)
- [Our Awards](#)
- [Advertise With Us](#)
- [Supporters](#)
- [Licensing Stories](#)

ACCOUNT

- [STAT+](#)
- [Group Subscriptions](#)
- [FAQ](#)
- [My Account](#)
- [Log In](#)
- [Subscribe](#)

MORE

- [Events](#)
- [Newsletters](#)
- [Reports](#)
- [App](#)
- [Podcasts](#)
- [Community](#)
- [STAT Trials Pulse](#)